Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 8Fallopian Tube Neoplasms 6Breast Neoplasms 5Sarcoma 3Ovarian Cancer Recurrent 3Carcinoma, Ovarian Epithelial 3Sarcoma, Ewing 2Neoplasm Metastasis 2Leiomyosarcoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Low Grade Serous Ovarian Cancer 1Liposarcoma 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1HER2-negative Breast Cancer 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Dermatofibrosarcoma 1

Interventions

Docetaxel 2Cisplatin 2130-nm albumin-bound paclitaxel 2taxane 1liposomal doxorubicin 1durvalumab 1cemiplimab 1atezolizumab 1Pemetrexed 1Paclitaxel 1Nivolumab 1Biosimilar Pharmaceuticals 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Vaccinia × liposomal doxorubicin × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡